Table 2.
Major ongoing clinical trials on Minimal Residual Disease in Acute Myeloid Leukemia in adults.
| Trial | Nation | ID | MRD-Related Endpoints | Type | Age Limits |
|---|---|---|---|---|---|
| MRC AML 17 | UK | ISRCTN55675535 | Assess the prognostic value of minimal residual disease monitoring (randomization: monitoring vs. not monitoring) | Phase 3 | <60 years |
| MRC AML 19 | UK | ISRCTN31682779 | Assess the prognostic value of minimal residual disease monitoring (randomization: monitoring vs. not monitoring) | Phase 3 | 18–60 years |
| MRC AML 18 | UK | ISRCTN78449203 | Treatment intensification in MRD+ patients after the first cycle, chemotherapy randomization | Phase 3 | >60 years |
| GIMEMA AML1310 | Italy | NCT01452646 | MRD stratification of intermediate-risk karyotype; risk-adapted, MRD-directed therapy (autoSCT vs. SCT) after first consolidation | Phase 2 | 18–60 years |
| CETLAM AML-03 | Spain | NCT01723657 | MRD stratification of intermediate-risk karyotype; risk-adapted, MRD-directed therapy (autoSCT vs. SCT) after first consolidation | Phase 2 | 18–70 years |
| PETHEMA LMA10 | Spain | NCT01296178 | Risk-adapted, MRD-directed therapy(study arms not provided) | Phase 3 | <65 years |
| PETHEMA | Spain | NCT00390715 | Prospective study on the prognostic value of baseline cytogenetics and MRD monitoring | Observational (prospective) | <65 years |
| Nanfang Hospital of Southern Medical University, Guangzhou | China | NCT02870777 | MRD-directed therapy for low- and intermediate-risk AML. Front-line allo-HSCT intensification is programmed for MRD+ patients | Phase 3 | 18–60 years |
| Rochester University | USA | NCT01311258 | Identification by MPFC, among all MRD cells, of the clones eventually responsible for clinical relapse (LIC) | Observational (prospective) | >18 years |
| Az. Ospedaliera Città della Salute e della Scienza Torino | Italy | NCT02714790 | Assess the prognostic role of MRD defined as BM expression of WT1 | Observational (retrospective) | >18 years |
| Medical College of Wisconsin | USA | NCT02349178 | Estimating the efficacy of Clofarabine, Cyclophosphamide and Etoposide in eliminating MRD in AML patients, otherwise in clinical remission, before allo-HSCT | Phase 2 | <40 years |
| Technische Universitat of Dresden RELAZA2 | Germany | EudraCT 2010-022388-37 | 5-Azacitidinetreatment of patients with MDS or AML with significant residual disease or an increase of MRD | Phase 2 | >18 years |
| Ulm University | Germany | NCT01770158 | Maintenance Therapy with Histamine Dihydrochloride and Interleukin-2 in AML MRD+ patients post consolidation therapy | Observational (prospective) | >18 years |
| Washington University | USA | NCT00863434 | Clofarabine and Cytarabine in treating MRD+ (by MPFC) AML patients | Phase 2 | 18–75 years |
| Singapore General Hospital | Singapore | NCT00394381 | Autologous Cytokine-induced Killer cell adoptive immunotherapy for MRD+ patients post autologous HSCT | Phase 1/2 | 12–75 years |
| Institute of Hematology & BloodDisease Hospital, Tianjin | China | NCT03021395 | Efficacy of maintenance Decitabine (after consolidation chemotherapy) in clearing MRD in patients in clinical remission | Phase 1/2 | 14–55 years |